CX-072 (pacmilimab), a Probody^®️ PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): an open-label dose-finding and first-in-human study

Naing A, Thistlethwaite F, De Vries EG, et al. Journal for ImmunoTherapy of Cancer 2021;9:e002447. doi: 10.1136/jitc-2021-002447